12:00 AM
 | 
Oct 25, 2004
 |  BioCentury  |  Strategy

Revving Newron's engine

Newron SpA has developed its ion channel discovery platform to the point where it is beginning to monetize its investment in areas outside of its core CNS focus. A case in point is its recent licensing deal with Dynogen Pharmaceuticals Inc., which is focused on ion channel modulators for gastrointestinal and genitourinary applications.

"Our platform is the result of efforts to set up functional assays targeting sodium and calcium channels," said CEO Luca Benatti.

The first...

Read the full 367 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >